Advertisement
CCXI vs SPRO
Which Stock Would AI Choose? Churchill Capital Corp XI (CCXI) vs. Spero Therapeutics (SPRO) Stock Comparison
Key Takeaways
- Different business models: CCXI is Churchill Capital Corp XI, a special purpose acquisition company (SPAC) pursuing a merger with Agility Robotics, while SPRO is Spero Therapeutics, a clinical-stage biopharmaceutical company.
- Distinct risk profiles: CCXI's value hinges on completing its business combination, whereas SPRO's outlook depends on drug approvals, royalty income, and clinical pipeline progress.
- Valuation gap: CCXI trades around $12 with a market capitalization of roughly $670 million, while SPRO trades near $1.14 with a market capitalization around $70 million.
- Recent catalysts: SPRO secured FDA (Food and Drug Administration) approval of Utebzi and a $105 million royalty financing, while CCXI's merger registration statement was recently declared effective.
- For more detail on key developments and intraday moves, explore CCXI Major News, CCXI Today's Price Move, SPRO Major News, and SPRO Today's Price Move.
- To see how AI-powered strategies are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating CCXI and SPRO are comparing two very different instruments. CCXI is Churchill Capital Corp XI, a special purpose acquisition company (SPAC) created to merge with a private business, while SPRO is Spero Therapeutics, a biotechnology firm developing antibiotics and immunology treatments. This stock comparison is relevant to traders seeking a SPAC tied to a high-profile merger target, as well as those following early-stage biotech catalysts. Understanding their relative performance, market positioning, and risk factors helps clarify which profile suits a given strategy.
CCXI Overview and Recent Performance
Churchill Capital Corp XI (CCXI) is a blank-check company founded by dealmaker Michael Klein that completed its initial public offering (IPO) in December 2025, raising $414 million. In June 2026, the company announced a definitive agreement to merge with Agility Robotics, a developer of humanoid robots, with the transaction's S-4 registration statement declared effective by the SEC in October 2026. In recent weeks, CCXI shares have traded meaningfully above their roughly $10-per-share trust redemption value, reflecting investor anticipation of the combination rather than operating fundamentals. Because the company has no operating history or revenue, its price behavior is driven largely by merger progress, redemption dynamics, and sentiment around the robotics sector.
SPRO Overview and Recent Performance
Spero Therapeutics (SPRO) is a clinical-stage biopharmaceutical company focused on treatments for multi-drug resistant infections and, more recently, immune-mediated diseases. In June 2026, the FDA approved Utebzi (tebipenem HBr), the first oral carbapenem antibiotic approved in the United States, for complicated urinary tract infections; GSK holds commercialization rights. Spero subsequently closed a $105 million non-dilutive royalty financing and in-licensed SP001, an anti-CD40L antibody candidate, from Innovent Biologics. Despite these milestones, SPRO shares have declined substantially over the past year and trade near $1.14, with the company reporting no revenue in its latest quarter and a net loss as it pivots toward immunology.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from hundreds of available automated strategies that trade thousands of different tickers. Only the bots best suited to current market conditions are featured, each with its own trading style, strategy, timeframe, performance record, statistics, and set of traded tickers. This diversity allows traders to compare approaches and identify systems aligned with their objectives. For those seeking a data-driven perspective on names like CCXI and SPRO, reviewing the Trending AI Robots page offers a practical starting point.
Head-to-Head Comparison
The two companies occupy entirely different segments. CCXI has no operating business; its relative performance reflects deal certainty and sentiment toward Agility Robotics, with downside anchored by the trust account redemption floor and upside tied to the merger closing and post-combination execution. SPRO, by contrast, is an operating biotech whose stock is driven by regulatory outcomes, milestone payments, and pipeline development. On risk, CCXI carries SPAC-specific risks including redemption risk and post-merger dilution, while SPRO faces clinical, regulatory, and funding risks despite a cash runway projected into the second half of 2029. On momentum, CCXI has shown strength above its redemption value in recent market activity, while SPRO has trended lower amid declining revenue and a shift in strategic focus.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalysts, Tickeron's AI would likely view CCXI as the more technically constructive of the two in the current environment, given its recent price strength above the trust floor and a defined near-term catalyst in the Agility Robotics combination. SPRO carries potentially significant upside from its Utebzi approval and royalty financing but currently exhibits weaker price stability. This assessment is probabilistic and based on recent conditions rather than a definitive forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCXI is a Buy and SPRO is a Hold.
CCXI in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
CCXI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 9 of 9 cases where CCXI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CCXI's RSI Indicator exited the oversold zone, 8 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CCXI as a result. In 15 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for CCXI just turned positive on November 03, 2026. Looking at past instances where CCXI's MACD turned positive, the stock continued to rise in 6 of 8 cases over the following month. The odds of a continued upward trend are 75%.
Following a +21.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCXI advanced for three days, in 51 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCXI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for CCXI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. CCXI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.338) is normal, around the industry mean (-543.087). P/E Ratio (-5.958) is within average values for comparable stocks, (118.532). Projected Growth (PEG Ratio) (2.600) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. CCXI's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCXI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
SPRO sees its Stochastic Oscillator climbs out of oversold territory
On November 09, 2026, the Stochastic Oscillator for SPRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 55 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 152 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SPRO entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.357) is normal, around the industry mean (3.498). P/E Ratio (7.357) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CCXI | SPRO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 48 | |
PRICE GROWTH RATING 1..100 | 63 | 82 | |
P/E GROWTH RATING 1..100 | 20 | 91 | |
SEASONALITY SCORE 1..100 | 58 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SPRO's Valuation (78) in the Pharmaceuticals Major industry is in the same range as CCXI (97) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CCXI’s over the last 12 months.
SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CCXI (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CCXI’s over the last 12 months.
SPRO's SMR Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CCXI (98) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CCXI’s over the last 12 months.
CCXI's Price Growth Rating (63) in the Biotechnology industry is in the same range as SPRO (82) in the Pharmaceuticals Major industry. This means that CCXI’s stock grew similarly to SPRO’s over the last 12 months.
CCXI's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for SPRO (91) in the Pharmaceuticals Major industry. This means that CCXI’s stock grew significantly faster than SPRO’s over the last 12 months.
| CCXI | SPRO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | N/A |
| Stochastic ODDS (%) | 2 days ago 56% | 1 day ago 80% |
| Momentum ODDS (%) | 2 days ago 63% | 1 day ago 87% |
| MACD ODDS (%) | 2 days ago 75% | 1 day ago 82% |
| TrendWeek ODDS (%) | 2 days ago 47% | 1 day ago 86% |
| TrendMonth ODDS (%) | 2 days ago 39% | 1 day ago 87% |
| Advances ODDS (%) | 8 days ago 65% | 3 days ago 73% |
| Declines ODDS (%) | 13 days ago 82% | 10 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 82% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CCXI’s FA Score shows that 1 FA rating(s) are green while SPRO’s FA Score has 0 green FA rating(s).
- CCXI’s FA Score: 1 green, 4 red.
- SPRO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CCXI’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 2 bullish TA indicator(s).
- CCXI’s TA Score: 5 bullish, 3 bearish.
- SPRO’s TA Score: 2 bullish, 6 bearish.
Price Growth
CCXI (@Financial Conglomerates) experienced а +5.33% price change this week, while SPRO (@Biotechnology) price change was -4.67% for the same time period.
The average weekly price growth across all stocks in the @Financial Conglomerates industry was +0.30%. For the same industry, the average monthly price growth was +0.14%, and the average quarterly price growth was +1.92%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
SPRO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Financial Conglomerates (+0.30% weekly)Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CCXI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CCXI has been loosely correlated with SPRO. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CCXI jumps, then SPRO could also see price increases.
| Ticker / NAME | Correlation To CCXI | 1D Price Change % | ||
|---|---|---|---|---|
| CCXI | 100% | N/A | ||
| SPRO - CCXI | 48% Loosely correlated | -5.61% | ||
| ABOS - CCXI | 48% Loosely correlated | -2.95% | ||
| ANVS - CCXI | 34% Loosely correlated | -3.00% | ||
| IPHA - CCXI | 34% Loosely correlated | +1.33% | ||
| IDYA - CCXI | 34% Loosely correlated | -0.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SMOT | 42.00 | 0.24 | +0.57% |
| VanEck Morningstar SMID Moat ETF (SMOT) | |||
| ITDB | 34.89 | 0.15 | +0.43% |
| iShares LifePath Target Date 2030 ETF (ITDB) | |||
| IDHQ | 44.41 | 0.11 | +0.25% |
| Invesco S&P International Developed High Quality ETF (IDHQ) | |||
| FIYY | 24.02 | 0.06 | +0.25% |
| GraniteShares YieldBOOST 20Y+ Treasuries ETF (FIYY) | |||
| GDOC | 39.51 | 0.10 | +0.25% |
| Future Health Care Equity ETF (GDOC) | |||